Global Subcutaneous Biologics Market Size To Exceed USD 5.86 Billion By 2035 | CAGR of 11.05%
Category: HealthcareGlobal Subcutaneous Biologics Market Size To Exceed USD 5.86 Billion By 2035
According to a research report published by Spherical Insights & Consulting, the Global Subcutaneous Biologics Market is Expected to Grow from USD 1.85 Billion in 2024 to USD 5.86 Billion by 2035, at a CAGR of 11.05% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 240 pages with 120 Market data tables and figures & charts from the report on the " Global Subcutaneous Biologics Market Size, Share, and COVID-19 Impact Analysis, By Type of Biologic (Antibodies, Nucleotides, and Proteins), By Method of Administration (Injection, Infusion, and Both (Injection & Infusion)), By Therapeutic Area (Autoimmune Disorders, Bone Diseases, Hematological Disorders, Infectious Diseases, Inflammatory Disorders, Metabolic Disorders, Neurological Disorders, Ocular Disorders, Oncological Disorders, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/subcutaneous-biologics-market
The subcutaneous biologics market is the industry encompassing the production, distribution, and sale of medications administered under the skin via subcutaneous injections. Subcutaneous biologics are complex therapeutic products, like vaccines, body proteins, and blood-derived products that are typically administered via intravenous and subcutaneous routes. Targeted treatment approaches with minimal drug interaction are responsible for driving the subcutaneous biologics market. An increasing demand for self-administerable therapies and the availability of user-friendly drug delivery devices are driving the market growth for subcutaneous biologics. The growing technological advancements in subcutaneous drug delivery, emphasizing patient compliance and improved treatment outcomes, are driving the subcutaneous biologics market. On the contrary, the subcutaneous biologics formulation and immunogenicity challenges associated with subcutaneous biologics are restraining the market.
The antibodies segment dominated the market with the largest market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type of biologic, the subcutaneous biologics market is divided into antibodies, nucleotides, and proteins. Among these, the antibodies segment dominated the market with the largest market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Reduced treatment burden and potential for subcutaneous self-administration of antibodies are the factors responsible for driving the market in the antibodies segment.
The injection segment accounted for a major share of the subcutaneous biologics market in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the method of administration, the subcutaneous biologics market is divided into injection, infusion, and both (injection & infusion). Among these, the injection segment accounted for a major share of the subcutaneous biologics market in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The reduced chance of allergic reaction and fluid overload, as well as the convenience of the injection method of administration, is contributing to driving the market growth.
The autoimmune disorders segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the therapeutic area, the subcutaneous biologics market is divided into autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders, and others. Among these, the autoimmune disorders segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. An increasing preference for subcutaneous injection among diabetic and obese patients is driving the market in the autoimmune disorders segment.
North America is expected to hold the majority share of the global subcutaneous biologics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global subcutaneous biologics market during the forecast period. Advanced biologic medicine, as well as the increased prevalence of chronic diseases in the region, are driving the market. In addition, the presence of biopharmaceutical companies and academic institutions in the region is propelling the subcutaneous biologics market.
Asia Pacific is anticipated to grow at the fastest pace in the global subcutaneous biologics market during the forecast period. An increasing demand for advanced therapeutics in subcutaneous biologics with the growing patient population, is propelling the market. Further, a number of collaborations between technology developers and drug developers lead to driving the market growth.
Middle East and Africa is expected to hold a substantial share of the subcutaneous biologics market during the predicted timeframe. The growing demand for precision medicine, along with the significant rise in biopharmaceutical industries in the region responsible for promoting market growth. In addition, increasing healthcare spending with the advancements in drug delivery technologies is contributing to driving the market.
Major vendors in the global subcutaneous biologics market are Adocia, Alteogen, Ascendis Pharma, CD Bioparticles, Creative Biolabs, Creative BioMart, Foresee Pharmaceuticals, Pacira Biosciences, Wyss Institute, Xeris Biopharma, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In July 2024, OneSource Specialty Pharma entered into a strategic licensing agreement with Bhami’s Research Laboratory. Partnership grants access to BRL’s HILOPRO technology, enhancing subcutaneous delivery of high-concentration biologic therapies and improving patient care.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Subcutaneous Biologics market based on the below-mentioned segments:
Global Subcutaneous Biologics Market, By Type of Biologic
- Antibodies
- Nucleotides
- Proteins
Global Subcutaneous Biologics Market, By Method of Administration
- Injection
- Infusion
- Both (Injection & Infusion)
Global Subcutaneous Biologics Market, By Therapeutic Area
- Autoimmune Disorders
- Bone Diseases
- Hematological Disorders
- Infectious Diseases
- Inflammatory Disorders
- Metabolic Disorders
- Neurological Disorders
- Ocular Disorders
- Oncological Disorders
- Others
Global Subcutaneous Biologics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?